berotek has been researched along with Airflow Obstruction, Chronic in 17 studies
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thirteen patients with chronic obstructive pulmonary disease (COPD) (FEV1, 32-75%pred) and 10 patients with asthma (FEV1, 43-75%pred) inhaled either 200 microg fenoterol or 200 microg oxitropium bromide or placebo, each of them on three occasions, on nine different days in a randomised, cross-over, double-blind fashion." | 5.10 | Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma. ( Eichler, G; Grönke, L; Jörres, RA; Kanniess, F; Magnussen, H; Mücke, M; Paasch, K; Richter, K; Taube, C, 2003) |
| " Analysis of the primary endpoint (change in forced expiratory volume in 1 s [FEV1] in the first 60 min after dosing [area under the curve; AUC0-1h]) on day 85 showed that the efficacy of Respimat SMI 20/50 (but not Respimat SMI 10/25) was not inferior to that of MDI 40/100." | 2.71 | Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. ( Beck, E; Bowen, I; Hesse, Ch; Kilfeather, SA; Lee, A; Ponitz, HH; Schmidt, P, 2004) |
| "Asthma and chronic obstructive pulmonary disease (COPD) can be effectively treated by the use of bronchodilator therapies delivered by inhalation." | 2.42 | A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. ( Bateman, ED; Hodder, R; Kässner, F, 2004) |
| "The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease (COPD) uses the post-bronchodilator spirometry for diagnosis and severity staging." | 1.35 | Severity staging of chronic obstructive pulmonary disease: differences in pre- and post-bronchodilator spirometry. ( Kuo, PH; Kuo, SH; Lin, SH; Yang, PC, 2009) |
| "Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases." | 1.33 | Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. ( Bagnardi, V; Corrao, G; Faini, S; Leoni, O; Suissa, S; Zambon, A, 2005) |
| "Ten patients with COPD who were intubated and mechanically ventilated received fenoterol (10 mg/4 mL) via the ventilator using a jet nebulizer for 30 min on ZEEPe and PEEPe set at 80% of the total PEEP in a random order." | 1.33 | Effects of inhaled fenoterol and positive end-expiratory pressure on the respiratory mechanics of patients with chronic obstructive pulmonary disease. ( Badet, M; Chantrel, G; Durand, PG; Guérin, C; Lemasson, S; Pereira, C; Philit, F; Poupelin, JC; Richard, JC; Vecellio, L, 2005) |
| "The study enrolled 20 COPD patients (mean age 64." | 1.32 | [Effects of nebuliser treatment with berotec on external respiratory function, bronchial permeability, hemodynamics, acid-alkaline balance, oxygen saturation, and their circadian structure in elderly patients with chronic obstructive pulmonary disease]. ( Akhmetov, KZh; Teĭblium, MM; Veklenko, GV; Zaslavskaia, RM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (82.35) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montoya-Giraldo, MA | 1 |
| Montoya, DV | 1 |
| Atehortúa, DA | 1 |
| Buendía, JA | 1 |
| Zuluaga, AF | 1 |
| Brand, P | 1 |
| Hederer, B | 1 |
| Austen, G | 1 |
| Dewberry, H | 1 |
| Meyer, T | 1 |
| Faisy, C | 1 |
| Pinto, FM | 1 |
| Blouquit-Laye, S | 1 |
| Danel, C | 1 |
| Naline, E | 1 |
| Buenestado, A | 1 |
| Grassin Delyle, S | 1 |
| Burgel, PR | 1 |
| Chapelier, A | 1 |
| Advenier, C | 1 |
| Candenas, ML | 1 |
| Devillier, P | 1 |
| Lorx, A | 1 |
| Szabó, B | 1 |
| Hercsuth, M | 1 |
| Pénzes, I | 1 |
| Hantos, Z | 1 |
| Lin, SH | 1 |
| Kuo, PH | 1 |
| Kuo, SH | 1 |
| Yang, PC | 1 |
| Oldenburger, A | 1 |
| Roscioni, SS | 1 |
| Jansen, E | 1 |
| Menzen, MH | 1 |
| Halayko, AJ | 1 |
| Timens, W | 1 |
| Meurs, H | 1 |
| Maarsingh, H | 1 |
| Schmidt, M | 1 |
| Taube, C | 1 |
| Kanniess, F | 1 |
| Grönke, L | 1 |
| Richter, K | 1 |
| Mücke, M | 1 |
| Paasch, K | 1 |
| Eichler, G | 1 |
| Jörres, RA | 1 |
| Magnussen, H | 1 |
| Zaslavskaia, RM | 1 |
| Veklenko, GV | 1 |
| Akhmetov, KZh | 1 |
| Teĭblium, MM | 1 |
| Kilfeather, SA | 1 |
| Ponitz, HH | 1 |
| Beck, E | 1 |
| Schmidt, P | 1 |
| Lee, A | 2 |
| Bowen, I | 1 |
| Hesse, Ch | 1 |
| Kässner, F | 1 |
| Hodder, R | 1 |
| Bateman, ED | 1 |
| Corrao, G | 1 |
| Zambon, A | 1 |
| Faini, S | 1 |
| Bagnardi, V | 1 |
| Leoni, O | 1 |
| Suissa, S | 1 |
| Guérin, C | 1 |
| Durand, PG | 1 |
| Pereira, C | 1 |
| Richard, JC | 1 |
| Poupelin, JC | 1 |
| Lemasson, S | 1 |
| Badet, M | 1 |
| Philit, F | 1 |
| Vecellio, L | 1 |
| Chantrel, G | 1 |
| Kerstjens, HA | 1 |
| Bantje, TA | 1 |
| Luursema, PB | 1 |
| Sinninghe Damste, HE | 1 |
| de Jong, JW | 1 |
| Wijker, SP | 1 |
| Cornelissen, PJ | 1 |
| Balestra, AM | 1 |
| Bingisser, RB | 1 |
| Chhajed, PN | 1 |
| Tamm, M | 1 |
| Leuppi, JD | 1 |
| Willaert, W | 1 |
| Daenen, M | 1 |
| Bomans, P | 1 |
| Verleden, G | 1 |
| Decramer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Acute Bronchodilator Effects of a Single Dose (2 Puffs) of the Shortacting Anticholinergic Ipratropium Bromide (40μg) and the Short-acting Beta-adrenergic Fenoterol (200μg) in Comparison to Placebo on Top of Pharmacodynamic Steady State of Once Daily [NCT00274066] | Phase 3 | 65 participants | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berotek and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aerosols; Asthma; Clinical Trials as Topic; Drug Combinations; Fenoterol | 2004 |
5 trials available for berotek and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Topics: Administration, Inhalation; Aerosol Propellants; Aerosols; Aged; Bronchodilator Agents; Cross-Over S | 2008 |
Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma.
Topics: Adrenergic beta-Agonists; Aged; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Meth | 2003 |
Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Double-Blind Meth | 2004 |
Effects of short-acting bronchodilators added to maintenance tiotropium therapy.
Topics: Bronchodilator Agents; Drug Therapy, Combination; Female; Fenoterol; Forced Expiratory Volume; Human | 2007 |
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Topics: Acute Disease; Aged; Albuterol; Bronchodilator Agents; Dyspnea; Female; Fenoterol; Glucocorticoids; | 2002 |
11 other studies available for berotek and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Myoclonus induced by salbutamol: A case report
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Combined Modality Therapy; Drug Synergism; Drug Ther | 2018 |
beta2-Agonist modulates epithelial gene expression involved in the T- and B-cell chemotaxis and induces airway sensitization in human isolated bronchi.
Topics: Adrenergic beta-Agonists; Aged; B-Lymphocytes; Bronchi; Bronchial Hyperreactivity; Bronchoconstricti | 2010 |
Low-frequency assessment of airway and tissue mechanics in ventilated COPD patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bronchodilator Agents; Drug Combinations; Female; Fen | 2009 |
Severity staging of chronic obstructive pulmonary disease: differences in pre- and post-bronchodilator spirometry.
Topics: Bronchodilator Agents; Fenoterol; Forced Expiratory Volume; Humans; Practice Guidelines as Topic; Pr | 2009 |
Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bronchi; Cell Nucleus; Cyclic AMP; Cyclic AMP-Dep | 2012 |
[Effects of nebuliser treatment with berotec on external respiratory function, bronchial permeability, hemodynamics, acid-alkaline balance, oxygen saturation, and their circadian structure in elderly patients with chronic obstructive pulmonary disease].
Topics: Acid-Base Equilibrium; Administration, Inhalation; Bronchi; Bronchodilator Agents; Fenoterol; Hemody | 2004 |
Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Dose-Response R | 2005 |
Effects of inhaled fenoterol and positive end-expiratory pressure on the respiratory mechanics of patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Combined Modality Therapy; Female; Feno | 2005 |
[Improved inhaler confirmed in general practice. Patients with respiratory diseases can breathe freely].
Topics: Aerosols; Asthma; Biological Availability; Bronchodilator Agents; Drug Combinations; Equipment Desig | 2006 |
[Inhalation system on trial. Current feasibility study data].
Topics: Asthma; Bronchodilator Agents; Drug Combinations; Family Practice; Feasibility Studies; Fenoterol; H | 2006 |
Bronchodilator response in residual volume in irreversible airway obstruction.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Bronchodilator Agents; Female; Fenoterol; Forced Ex | 2008 |